Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 1,905 phantom stock units through the company's deferred compensation plan.

Summary

• On March 14, 2025, Albert Bourla, the Chairman and CEO of Pfizer Inc., acquired 1,905 phantom stock units.
• The acquisition was made through the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Each unit represents one phantom share of Pfizer common stock.
• The price of the underlying common stock at the time of the transaction was $25.72.
• Following the transaction, Bourla directly owns 705,449 shares of Pfizer common stock.
• The phantom stock units are settled in cash following Bourla's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives who participate in deferred compensation plans. It provides transparency into the holdings of company leadership.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves phantom stock units acquired through a deferred compensation plan.

Key Dates